Sparks - BB Biotech

BB Biotech (BION) delivered a strong Q226, with NAV rising 17.2% in Swiss franc terms and outperforming the Nasdaq Biotechnology Index by 3.5pp, supported by positive clinical developments and continued sector M&A activity. The share price generated a total return of 9.7%, although the discount to NAV widened to 12.9% at 30 June 2026. BION initiated 12 investments during the quarter, taking the portfolio to 39 positions, while increasing exposure to more established biotechnology companies to improve resilience alongside its core holdings in innovative smaller and mid-sized businesses. Three portfolio companies have been involved in acquisitions during 2026 to date, with eight portfolio companies targeted over the past six quarters, highlighting continued pharmaceutical industry demand for differentiated biotechnology assets.

Management remains constructive on the medium-term biotechnology outlook, citing a strong pipeline of clinical and regulatory catalysts, while acknowledging that stock selection has become increasingly important following the sector’s recovery.